Cleveland Cofield
Reviews 1

👍 I've had a great experience with Ambit! They are experts in the biotech industry and their website, ambitbio.com, is user-friendly. The team is always helpful and the services provided are exceptional. I highly recommend them! 👏

Sue Hoskin
Reviews 1

I recently worked with a company specializing in biotechnology. The services and knowledge they provided were top-notch. I was impressed with their professionalism and efficiency. I would definitely recommend their services to others.

Nathan Bleigh
Reviews 1

I recently had the opportunity to work with a company that specializes in biotechnology. Their website, ambitbio.com, provided detailed information about their services. It was a positive experience overall, and I would recommend them to others.

News & Press

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying widget on your website — its a simple way to convert your visitors into customers.

Embed code

<script src="https://trustburn.com/widgets/index.js"></script>
<div class="trustburn-widget" data-trustburn-protocol="https:" data-trustburn-domain="trustburn.com" data-trustburn-widget="score" data-company-path="ambit" data-lang="en"></div>
More widgets

About Ambit

Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other indications. Ambit's lead compound, AC220, is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML. Ambit is developing AC220 in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to AC220, Ambit's clinical pipeline includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. Ambit also has a pipeline of preclinical candidates which includes CEP-32496, a BRAF inhibitor licensed to Cephalon.

Categories
Biotechnology